Can AI catch the leading cause of blindness before It's too late?

NCT ID NCT05704491

First seen Aug 10, 2026 · Last updated Aug 11, 2026 · Updated 1 time

Summary

This trial is testing whether an artificial intelligence (AI) model, called MONA DR, can accurately detect diabetic retinopathy—a common eye complication of diabetes that can lead to blindness—from retinal photographs. The study will enroll 100 adults with diabetes and compare the AI's readings against standard assessments to measure its accuracy. If the AI proves reliable, it could offer a faster, more accessible screening option for the millions of people who need annual eye exams.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
An artificial intelligence (AI) algorithm called the MONA DR model, which analyzes retinal images to detect diabetic retinopathy.
What this could lead to
If successful, this AI could provide a reliable, fast, and accessible screening tool for diabetic retinopathy, potentially preventing vision loss in millions.
What could go wrong
The trial is relatively small (100 participants) and focuses on diagnostic accuracy, not long-term outcomes. The AI's performance in this specific group may not generalize to all populations or settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • West German Center of Diabetes and Health

    RECRUITING

    Düsseldorf, 40591, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.